Literature DB >> 31668552

Posterior Reversible Encephalopathy Syndrome Instigated by Off-Label Disulfiram Use for Metastatic Melanoma.

David R Beam1, Jennifer M Knight2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31668552      PMCID： PMC7075719          DOI： 10.1016/j.psym.2019.09.003

Source DB:  PubMed          Journal:  Psychosomatics        ISSN： 0033-3182            Impact factor:   2.386


× No keyword cloud information.
  19 in total

1.  Posterior reversible encephalopathy syndrome following disulfiram intoxication.

Authors:  Sandra Coppens; Gilles Naeije; Nicolas Mavroudakis
Journal:  J Neurol       Date:  2011-02-22       Impact factor: 4.849

2.  Disulfiram reaction in an artist exposed to solvents.

Authors:  R I Ehrlich; D C S Woolf; D A Kibel
Journal:  Occup Med (Lond)       Date:  2011-11-07       Impact factor: 1.611

3.  A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.

Authors:  Jiayi Huang; Rekha Chaudhary; Adam L Cohen; Karen Fink; Samuel Goldlust; John Boockvar; Prakash Chinnaiyan; Leping Wan; Stephen Marcus; Jian L Campian
Journal:  J Neurooncol       Date:  2019-02-15       Impact factor: 4.130

4.  A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.

Authors:  Jiayi Huang; Jian L Campian; Amit D Gujar; David D Tran; A Craig Lockhart; Todd A DeWees; Christina I Tsien; Albert H Kim
Journal:  J Neurooncol       Date:  2016-03-10       Impact factor: 4.130

5.  Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice.

Authors:  Brooke N Bourdélat-Parks; George M Anderson; Zoe R Donaldson; Jay M Weiss; Robert W Bonsall; Milburn S Emery; L Cameron Liles; David Weinshenker
Journal:  Psychopharmacology (Berl)       Date:  2005-10-22       Impact factor: 4.530

Review 6.  Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.

Authors:  Maricela Viola-Rhenals; Kush R Patel; Laura Jaimes-Santamaria; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Curr Med Chem       Date:  2018-02-12       Impact factor: 4.530

7.  Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping.

Authors:  K J Ahn; W J You; S L Jeong; J W Lee; B S Kim; J H Lee; D W Yang; Y M Son; S T Hahn
Journal:  Neuroradiology       Date:  2004-11-05       Impact factor: 2.804

8.  Can dopamine beta-hydroxylase levels predict adverse reactions to disulfiram?

Authors:  J A Ewing; B A Rouse; R A Mueller; D Silver
Journal:  Alcohol Clin Exp Res       Date:  1978-01       Impact factor: 3.455

9.  Disulfiram-induced reversible hypertension: a prospective case series and review of the literature.

Authors:  Ranganath R Kulkarni; Santosh I Ramdurg; Bhavya K Bairy
Journal:  Indian J Psychol Med       Date:  2014-10

10.  Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.

Authors:  Bing Xu; Shiyun Wang; Rongwei Li; Kai Chen; Lingli He; Manman Deng; Vinodh Kannappan; Jie Zha; Huijuan Dong; Weiguang Wang
Journal:  Cell Death Dis       Date:  2017-05-18       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.